Last updated on May 2018

Ketamine for Reduction of Alcoholic Relapse

Brief description of study

96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation. Patients will be assessed at 3 and 6 months on a range of psychological and biological variables. Primary endpoints will be % days abstinent at 3 and 6 months and relapse rates at 6 months. Secondary endpoints include depressive symptoms, craving, quality of life.

Clinical Study Identifier: NCT02649231

Contact Investigators or Research Sites near you

Start Over

Amy McAndrew, PhD

NIHR Exeter Clinical Research Facility
Exeter, United Kingdom
  Connect »

Beth Marsh, PhD

NIHR/Wellcome UCLH Research Facility
London, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.